NCT02862028

PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach)

A Clinical Study of PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach)

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Shanghai International Medical Center · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Objectives: To evaluate the safety and effectiveness of cell therapy using herinCAR-PD1 cells to treat relapsed or refractory cancer. Eligibility: Individuals greater than or equal to 18 years of age and less than or equal to 70 years of age who have been diagnosed with relapsed or refractory cancer that has not responded to or has relapsed after standard treatment.

Detailed description

A total of 20 patients may be enrolled over a period of 1-2 years.

Conditions

• PD-1 Antibody
• CAR-T Cells
• Advanced Solid Tumor

Interventions

Type	Name	Description
BIOLOGICAL	HerinCAR-PD1 cells	herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.

Timeline

• Start date: 2016-08-01
• Primary completion: 2018-03-01
• Completion: 2018-07-01
• First posted: 2016-08-10
• Last updated: 2016-08-25

Locations

1 site across 1 country: China